The Seattle-based company executed a $4 million close as part of this investment with Lind Global Fund II. The Lind Partners, a New York-based institutional fund manager, manages Lind Global Fund II.
Funding helps Know Labs work toward bringing its non-invasive continuous glucose monitoring (CGM) technology to market. The company unveiled KnowU, its wearable CGM set for FDA submission, earlier this week. KnowU’s sensor uses spectroscopy to direct electromagnetic energy through a substance or material. Through this, it can capture a unique molecular signature. The technology integrates into wearable, mobile or bench-top form factors.
Get the full story at our sister site, Drug Delivery Business News.